NICE
NICE recommends Bayer’s Xofigo for prostate cancer treatment
September 2, 2016Medical Communications, Sales and Marketing Bayer, NICE, approval, prostate cancer, recommendation, xofigo
NICE has issued final draft guidance recommending Bayer’s Xofigo (radium-223 dichloride) for the treatment of prostate cancer. Previously, the drug …
NICE approves lung cancer and leukaemia treatments
August 24, 2016Research and Development, Sales and Marketing Alimta, CDF, NICE, bosulif, bosutinib, pemetrexed
The National Institute for Health and Care Excellence (NICE) has issued its approval of two drugs for routine use on …
NICE recommends Eylea as first-line treatment for sight threatening condition
August 24, 2016Research and Development, Sales and Marketing Bayer, Eylea, NHS, NICE, first-line treatment
Bayer has announced that the National Institute for Health and Care Excellence (NICE) has recommended Eylea (aflibercept) as a cost-effective …
Bayer’s liver cancer drug not cost-effective, says NICE
August 19, 2016Medical Communications, Sales and Marketing Bayer, CDF, NICE, Nexavar, lung cancer
NICE has deemed Bayer’s liver cancer drug Nexavar (sorafenib) as not cost-effective. The drug is currently available on the Cancer …
Pfizer’s Xalkori price drop secures NICE recommendation
August 18, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, Pfizer, Xalkori, crizotinib, lung cancer
The National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Xalkori (crizotinib) as a treatment for lung cancer, …
NICE says Afinitor and Imbruvica “may be removed” from Cancer Drugs Fund
August 18, 2016Research and Development, Sales and Marketing Afinitor, Cancer Drugs Fund, Janssen, NICE, Novartis, imbruvica
NICE has published draft guidance advising the removal of Novartis’s Afinitor (everolimus) and Janssen’s Imbruvica (ibrutinib) from the Cancer Drugs …
Old CDF drug not recommended in initial NICE guidance due to lack of evidence
August 10, 2016Research and Development, Sales and Marketing Adcetris, Cancer Drugs Fund, NICE, Takeda, hodgkin's lymphoma
The National Institute for Health and Care Excellence (NICE) has published draft guidance not recommending Takeda’s Adectris (brentuximab vedotin), despite …
NICE recommends Amgen’s Imlygic for advanced skin cancer
August 9, 2016Manufacturing and Production, Sales and Marketing Amgen, Imlygic, NICE, skin cancer
NICE has published its final draft guidance recommending Amgen’s Imlygic (talimogene laherparepvec) for the treatment of advanced melanoma in adults …
Top ten stories in the pharmaceutical industry this week
August 5, 2016Medical Communications, Research and Development Actavis, Bioelectronics, CDF, Celgne, EMA, GSK, GlaxoSmithKline, Innovate UK, Medivation, NICE, Novartis, Roche, Sanofi, Teva, appointments, apremilast, biog, breast cancer, brexit, google, pharmaceutical industry, rheumatoid arthritis, sarilumab, top ten
It’s Friday, and we’ve seen some big developments in the industry’s headlines throughout the week, from news of Glaxo-Smith-Kilne’s new …
NICE recommends Cosentyx in ankylosing spondylitis
August 4, 2016Research and Development, Sales and Marketing Cosentyx, NICE, Novartis, ankylosing spondylitis
Novartis has announced that the National Institute for Health and Care Excellence (NICE) has recommended Cosentyx (secukinumab) to treat adults …
Celgene’s Otezla approved for NHS use
August 3, 2016Research and Development, Sales and Marketing Celgene, NHS, NICE, apremilast
NICE has published draft guidance recommending the use of Celgene’s Otezla (apremilast) for use on the NHS for treatment of …
Evaluation of Eisai’s advanced thyroid cancer treatment blocked until 2018 in England
August 2, 2016Manufacturing and Production, Sales and Marketing CDF, Eisai, Lenvima, NHS, NICE, lenvatinib, thyroid cancer
Following negotiations between the NHS, NICE and Japanese pharmaceutical company Eisai, differentiated thyroid cancer (RAI-R DTC) drug lenvima (levatinib) has …
Roche urges reform of Cancer Drugs Fund as NICE takes control
July 29, 2016Medical Communications, Research and Development, Sales and Marketing CDF, Cancer Drugs Fund, NICE, Roche
Roche has warned that cancer patients in England are facing into an “uncertain future” as the new Cancer Drugs Fund …
Shire and BMS secure NICE recommendations for oncology drugs
July 27, 2016Research and Development, Sales and Marketing BMS, Baxalta, NICE, Oncaspar, Shire, Yervoy, opdivo
The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending Shire’s Oncaspar (pegaspargase) and Bristol-Myers Squibb’s …
Nice rejects United Therapeutics’ cancer drug
July 15, 2016Medical Communications, Research and Development NICE, United Therapeutics, Unituxin, neuroblastoma
The National Institute for Health and Care Excellence (Nice) rejected United Therapeutics’ (Nasdaq: UTHR) Unituxin (dinutuximab) in combination therapy to …
Latest content
FibroFind appoints Lee Borthwick as CEO
